Coherus BioSciences, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for CHRS, updated each market day.
CHRS AI Sentiment
AI sees no strong directional signal for Coherus BioSciences, Inc. stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Coherus BioSciences, Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
Sector
Exchange
Market Cap
$247,318,338
Cap Tier
Employees
147
Headquarters
REDWOOD CITY, CA
Listed Since
Nov. 6, 2014
Website
CHRS Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
CHRS Volatility
Coherus BioSciences, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
